XXII - 22nd Century Group, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.9648
-0.0052 (-0.54%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.9700
Open0.9800
Bid0.9528 x 1000
Ask0.9435 x 900
Day's Range0.9400 - 0.9800
52 Week Range0.7000 - 2.5900
Volume903,225
Avg. Volume2,476,983
Market Cap129.688M
Beta (5Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-0.2350
Earnings DateNov 07, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
  • Business Wire

    FDA Scientific Advisory Committee Discusses 22nd Century Group’s Reduced Nicotine Cigarettes

    22nd Century Group, Inc. (NYSE American: XXII) — a plant biotechnology company that is a leader in reduced nicotine tobacco and hemp/cannabis plant research — met on Friday, February 14, 2020 with the U.S. Food and Drug Administration’s Tobacco Product Scientific Advisory Committee (TPSAC) to present the Company’s Modified Risk Tobacco Product (MRTP) application for its proprietary, reduced nicotine content cigarettes. This meeting was the first time that TPSAC considered an MRTP application for a modified exposure claim and also TPSAC's first discussion of an application for a combustible tobacco product.

  • Business Wire

    22nd Century Group’s FDA Advisory Committee Meeting for Reduced Nicotine Content Cigarettes Brings New Standard for the Tobacco Industry

    22nd Century Group, Inc. (NYSE American: XXII)—a plant biotechnology company that is a leader in tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis plant research—will present the Company’s Modified Risk Tobacco Product (MRTP) application for its reduced nicotine content cigarettes to the U.S. Food and Drug Administration’s Tobacco Product Scientific Advisory Committee (FDA TPSAC) on Friday, February 14, 2020. This meeting will be the first TPSAC meeting to review a combustible tobacco product application, and the first time it has reviewed a modified exposure claim application.

  • If You Had Bought 22nd Century Group (NYSEMKT:XXII) Stock A Year Ago, You'd Be Sitting On A 50% Loss, Today
    Simply Wall St.

    If You Had Bought 22nd Century Group (NYSEMKT:XXII) Stock A Year Ago, You'd Be Sitting On A 50% Loss, Today

    It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...

  • GlobeNewswire

    22nd Century Group Appoints New Director and New Chairman

    Williamsville, NY, Jan. 13, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced the appointment of Roger O’Brien as a new member of 22nd Century Group’s Board of Directors (the “Board”) and the appointment of Nora Sullivan, an existing director of the Board, as the new Chairman of the Board.

  • GlobeNewswire

    22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee

    Williamsville, NY, Dec. 23, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced today that the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) will conduct a public hearing on Friday, February 14, 2020, regarding 22nd Century Group’s Modified Risk Tobacco Product (MRTP) application for its VLNC cigarettes under the proposed brand name of VLN® cigarettes. “We welcome the opportunity to publicly present our MRTP application and detail the science and evidence supporting the reduced exposure claims for VLN® cigarettes,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.

  • GlobeNewswire

    FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes

    Williamsville, NY, Dec. 17, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the U.S. Food and Drug Administration (FDA) has found that the marketing of 22nd Century Group’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes are “appropriate for the protection of the public health,” and the FDA has issued marketing orders to permit the sale of these products in the U.S. This FDA authorization follows the FDA’s review of the Premarket Tobacco Product Applications (PMTA) previously submitted by 22nd Century Group. “FDA authorization of 22nd Century’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes is a major milestone in our efforts to drive meaningful change in the tobacco industry,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.

  • GlobeNewswire

    22nd Century Group Announces Management Changes

    Williamsville, NY, Dec. 13, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today changes to the Company’s management. “Over the past few months we have made rapid and significant progress in strengthening 22nd Century Group as we execute against our two growth strategies,” commented James W. Cornell, Director & Chairman of the Board of 22nd Century Group.

  • Benzinga

    22nd Century Enters CBD Space With $24M Investment In Panacea

    Investments are anticipated to total $24 million, in a combination of cash and 22nd Century stock. “Our objective is to build a leading, profitable business in the fast-growing, emerging, legal hemp/cannabis space, and Panacea is a rapidly-growing, vertically-integrated, consumer-facing business with a very strong management team," Cliff Fleet, President and CEO of 22nd Century Group said in a statement.

  • GlobeNewswire

    22nd Century Group Enters CBD Health and Wellness Market with Investment in Panacea Life Sciences, Inc.

    Williamsville, NY, Dec. 03, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today the initial closing of an investment in Panacea Life Sciences, Inc. (Panacea), a rapidly-growing, vertically-integrated, consumer-facing company operating exclusively in the legal, hemp-derived, CBD product space. 22nd Century’s investments in Panacea over the next twelve to eighteen months are expected to total $24 million, in a combination of cash and 22nd Century stock in exchange for Panacea-issued debt and preferred equity.

  • Thomson Reuters StreetEvents

    Edited Transcript of XXII earnings conference call or presentation 8-Nov-19 2:00pm GMT

    Q3 2019 22nd Century Group Inc Earnings Call

  • GlobeNewswire

    22nd Century Group Comments on Delay of Reduced Nicotine Rule for Cigarettes

    Williamsville, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, responded today to the FDA’s recent removal of the Tobacco Product Standard for Nicotine Level of Certain Tobacco Products from the Trump administration’s ‘unified agenda.’  The much anticipated Notice of Proposed Rulemaking (NPRM) for the reduced nicotine product standard, which was expected in October, was listed as being “Withdrawn” as of October 23, 2019, on the White House Office of Information and Regulatory Affairs website. The unified agenda was updated with the new information on Wednesday, November 20, 2019, as part of a semiannual review.

  • GlobeNewswire

    22nd Century Group Announces Webcast to Provide Business Update

    WILLIAMSVILLE, NY -- 22nd Century Group, Inc. (NYSE American:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the Company will provide a business update for investors via an audio-only webcast on Friday, November 8, 2019, at 9:00 AM Eastern time. Cliff Fleet, Chief Executive Officer of 22nd Century Group, together with John Brodfuehrer, Chief Financial Officer, will conduct the webcast. Interested parties are invited to listen to the live event on the 22nd Century website: www.xxiicentury.com/media/2019Q3BusinessUpdate.

  • Does 22nd Century Group (NYSEMKT:XXII) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does 22nd Century Group (NYSEMKT:XXII) Have A Healthy Balance Sheet?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Trump May Ban Flavored E-Cigarettes: Who Wins, Who Loses
    Zacks

    Trump May Ban Flavored E-Cigarettes: Who Wins, Who Loses

    Vaping is a growing trend among youngsters, but Trump's recent threat to ban flavored e-cigarettes raises questions. Will traditional cigarette get back its lost glory?

  • 3 Pot Stocks to Avoid Like the Plague in September
    Motley Fool

    3 Pot Stocks to Avoid Like the Plague in September

    These marijuana stocks are unlikely to have investors seeing green in the near term.

  • Only These 10 Pot Stocks Ended August Higher
    Motley Fool

    Only These 10 Pot Stocks Ended August Higher

    Despite another miserable month for marijuana stocks, these companies managed to buck the trend.

  • 3 Best Marijuana Stocks of August -- Are They Buys Now?
    Motley Fool

    3 Best Marijuana Stocks of August -- Are They Buys Now?

    Most pot stocks performed poorly last month, but not these three highfliers.

  • GuruFocus.com

    22nd Century Group Inc (XXII) President and CEO Clifford B Fleet Bought $190,000 of Shares

    President and CEO of 22nd Century Group Inc (30-Year Financial, Insider Trades) Clifford B Fleet (insider trades) bought 100,000 shares of XXII on 08/27/2019 at an average price of $1.9 a share. Continue reading...

  • Will 22nd Century Group Continue to Surge Higher?
    Zacks

    Will 22nd Century Group Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor 22nd Century Group.

  • 22nd Century Group, Inc. (NYSEMKT:XXII): What Does Its Beta Value Mean For Your Portfolio?
    Simply Wall St.

    22nd Century Group, Inc. (NYSEMKT:XXII): What Does Its Beta Value Mean For Your Portfolio?

    If you're interested in 22nd Century Group, Inc. (NYSEMKT:XXII), then you might want to consider its beta (a measure...

  • Thomson Reuters StreetEvents

    Edited Transcript of XXII earnings conference call or presentation 8-Aug-19 8:00pm GMT

    Q2 2019 22nd Century Group Inc Earnings Call

  • 22nd Century Group Inc (XXII) Q2 2019 Earnings Call Transcript
    Motley Fool

    22nd Century Group Inc (XXII) Q2 2019 Earnings Call Transcript

    XXII earnings call for the period ending June 30, 2019.